JMP Securities Reaffirms “Market Outperform” Rating for DBV Technologies (NASDAQ:DBVT)

JMP Securities reiterated their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other equities research analysts also recently issued reports on the stock. StockNews.com began coverage on shares of DBV Technologies in a report on Sunday, December 8th. They set a “hold” rating on the stock. HC Wainwright raised their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $3.84 on Tuesday. The stock has a market cap of $78.98 million, a price-to-earnings ratio of -0.85 and a beta of 0.64. The business has a 50 day simple moving average of $3.45 and a 200 day simple moving average of $4.04. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $10.70.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.